Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer

Huang,Xiaoping; Wei,Qingzhu; Liu,Jianghuan; Niu,Hongling; Xiao,Gang; Liu,Lixin

doi:10.3892/ol.2017.7161

Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer

Authors:
- Xiaoping Huang
- Qingzhu Wei
- Jianghuan Liu
- Hongling Niu
- Gang Xiao
- Lixin Liu
View Affiliations

Affiliations: Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China, Department of Pathology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/ol.2017.7161
Pages: 7304-7310
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor II mRNA‑binding protein 3 (IMP3) is an oncofetal protein upregulated in tumor cells during carcinogenesis. The aim of the present study was to investigate the expression status of IMP3 in colorectal cancer (CRC) tissues and its clinical significance. Immunostaining was performed in 130 CRC samples, the association of IMP3 expression with clinicopathological characteristics was assessed and 58 patients were selected for survival analysis. To the best of our knowledge, the present study describes for the first time the expression of IMP3 in tumor stromal components of CRC. Stromal expression of IMP3 was detected in 24/130 (18.5%) CRC tissue specimens and was associated with tumor‑node‑metastasis (TNM) stage (stage III‑IV, P=0.003), lymph node metastasis (P=0.006), lympho‑vascular invasion (P=0.003), tumor border (P=0.013). Tumoral expression of IMP3 was detected in 94/130 (72.3%) of CRC specimens and was associated with T classification (T3‑T4, P=0.027), tumor‑node‑metastasis (TNM) stage (stage III‑IV, P=0.011), lymph node metastasis (P=0.048), tumor budding (>10 buds, P=0.005). Further study indicated that patients with IMP3 expressed in tumor cells and tumor stroma tend to have poorer overall survival rates (P=0.02 and P=0.06, respectively). Moreover, tumoral expression of IMP3 and TNM stage were identified to be independent prognostic factors in CRC. IMP3 was not only expressed in tumor cells but also in stroma cells. Stromal expression of IMP3 was associated with lymph node metastasis and advanced tumor TNM stage. Moreover, the survival analysis indicated that there is a significant association between IMP3 expression in tumor cells and a poorer overall survival rate in patients with CRC. The expression of IMP3 maybe a predicted factor for CRC patient.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C, et al: Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 47:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
3	Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcessepe P, Imbriani GC, Remo A and Pancione M: Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: Role of aflibercept. Gastroenterol Res Pract. 2014:5261782014. View Article : Google Scholar : PubMed/NCBI
4	Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, et al: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 14:2729–2733. 1997. View Article : Google Scholar : PubMed/NCBI
5	Liao B, Hu Y, Herrick D and Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during prolifearation of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005. View Article : Google Scholar : PubMed/NCBI
6	Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gong Y, Woda BA and Jiang Z: Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 21:191–200. 2014. View Article : Google Scholar : PubMed/NCBI
8	Mueller F, Bommer M, Lacher U, Ruhland C, Stagge V, Adler G, Gress TM and Seufferlein T: KOC is a novel molecular indicator of malignancy. Br J Cancer. 88:699–701. 2003. View Article : Google Scholar : PubMed/NCBI
9	Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH and Jeng YM: Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 16:1711–1719. 2009. View Article : Google Scholar : PubMed/NCBI
10	Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 12:3499–3506. 2009. View Article : Google Scholar
11	Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, et al: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 48:3405–3413. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L and Chen L: Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett. 6:740–744. 2013.PubMed/NCBI
13	Herrera M, Islam AB, Herrera A, Martín P, García V, Silva J, Garcia JM, Salas C, Casal I, de Herreros AG, et al: Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. 19:5914–5926. 2013. View Article : Google Scholar : PubMed/NCBI
14	Fidler IJ: The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003. View Article : Google Scholar : PubMed/NCBI
15	Bhowmick NA and Moses HL: Tumor-stroma interactions. Curr Opin Genet Dev. 15:97–101. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang J and Liu J: Tumor stroma as targets for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : PubMed/NCBI
17	Massoner P, Haag P, Seifarth C, Jurgeit A, Rogatsch H, Doppler W, Bartsch G and Klocker H: Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: Local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction. Prostate. 68:1165–1178. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
19	Prall F: Tumour budding in colorectal carcinoma. Histopathology. 50:151–162. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hase K, Shatney CH, Mochizuki H, Johnson DL, Tamakuma S, Vierra M and Trollope M: Long-term results of curative resection of ‘minimally invasive’ colorectal cancer. Dis Colon Rectum. 38:19–26. 1995. View Article : Google Scholar : PubMed/NCBI
21	Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO classification of tumours of the digestive system, Fourth Edition. WHO Classif Tumours Digestive System. 3:2010
22	O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425. 2004. View Article : Google Scholar : PubMed/NCBI
23	Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K and Lugli A: Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 26:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
24	Bissell MJ and Radisky D: Putting tumours in context. Nat Rev Cancer. 1:46–54. 2001. View Article : Google Scholar : PubMed/NCBI
25	Calorin L and Bianchini F: Environmental control of invasiveness and metastatic dissenmination of tumor cells: The role of tumor cell-host cell interations. Cell Commun Signal. 8:242010.PubMed/NCBI
26	Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schäfer G, Klocker H and Berger P: Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. Endocrinology. 154:2586–2599. 2013. View Article : Google Scholar : PubMed/NCBI
27	Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M: Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 13:2082–2090. 2007. View Article : Google Scholar : PubMed/NCBI
28	Zlobec I and Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget. 1:651–661. 2010. View Article : Google Scholar : PubMed/NCBI
29	Giger OT, Comtesse SC, Lugli A, Zlobec I and Kurrer MO: Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol. 25:1048–1053. 2012. View Article : Google Scholar : PubMed/NCBI
30	van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, et al: EURECCA colorectal: Multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 49:2784–2790. 2013. View Article : Google Scholar : PubMed/NCBI
31	Ahmed S, Johnson K, Ahmed O and Iqbal N: Advances in the management of colorectal cancer: From biology to treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
32	Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
33	Nishio K, Inoue A, Qiao S, Kondo H and Mimura A: Senescence and cytoskeleton: Overproduction of vimentin induces senescent-like morphology in human fibroblast. Histochem Cell Biol. 116:321–327. 2001. View Article : Google Scholar : PubMed/NCBI